{
  "guideline": {
    "id": "PA166110235",
    "name": "Annotation of CPIC Guideline for peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and IFNL3",
    "source": "CPIC",
    "version": 47,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166110235",
    "relatedChemicals": [
      {
        "id": "PA164749390",
        "name": "peginterferon alfa-2a",
        "symbol": null
      },
      {
        "id": "PA164784024",
        "name": "peginterferon alfa-2b",
        "symbol": null
      },
      {
        "id": "PA451241",
        "name": "ribavirin",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA134952671",
        "name": "interferon lambda 3",
        "symbol": "IFNL3"
      }
    ],
    "recommendation": true
  },
  "recommendations": [],
  "citations": [
    {
      "pmid": "24096968",
      "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-alpha-based regimens.",
      "authors": [
        "Muir A J",
        "Gong L",
        "Johnson S G",
        "Lee M T M",
        "Williams M S",
        "Klein T E",
        "Caudle K E",
        "Nelson D R",
        "Clinical Pharmacogenetics Implementation Consortium (CPIC)"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2014,
      "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904555"
    }
  ],
  "version": "2024-02-29-20-19"
}